Z Squared (ZSQR) Q2 2024 earnings summary

Executive summary

• Focused on developing cell therapy technologies for cancer and other diseases, with ongoing investments in innovative products and strategic partnerships.

• Minimal revenue generated, with primary activities centered on product development, capital raising, and infrastructure building.

• Recent exclusive licensing and asset purchase agreements expand the technology portfolio, including partnerships with Vy-Gen Bio and Deverra Therapeutics.

Financial highlights

• Net loss for Q2 2024 was $3.0 million, compared to $3.2 million in Q2 2023; net loss for the six months ended June 30, 2024 was $6.0 million, down from $11.2 million year-over-year.

• Operating expenses decreased to $2.8 million in Q2 2024 from $3.7 million in Q2 2023, mainly due to lower professional services expenses.

• Cash and cash equivalents increased to $1.6 million as of June 30, 2024, from $1.5 million at year-end 2023.

• Stock-based compensation expense rose to $611,570 in Q2 2024 from $113,391 in Q2 2023.

Outlook and guidance

• Management does not expect significant revenue for at least the next two years as drug development continues.

• Plans to increase liquidity and support operations through additional capital raises and equity transactions.